JP2012528857A - 純粋ｐｅｇ−脂質コンジュゲート - Google Patents

純粋ｐｅｇ−脂質コンジュゲート Download PDF

Info

Publication number
JP2012528857A
JP2012528857A JP2012513928A JP2012513928A JP2012528857A JP 2012528857 A JP2012528857 A JP 2012528857A JP 2012513928 A JP2012513928 A JP 2012513928A JP 2012513928 A JP2012513928 A JP 2012513928A JP 2012528857 A JP2012528857 A JP 2012528857A
Authority
JP
Japan
Prior art keywords
peg
glycerol
lipid
glycol
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012513928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012528857A5 (enExample
Inventor
ウー，ニエン
ケラー，ブライアン，チャールズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2012528857A publication Critical patent/JP2012528857A/ja
Publication of JP2012528857A5 publication Critical patent/JP2012528857A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L63/00—Compositions of epoxy resins; Compositions of derivatives of epoxy resins
    • C08L63/10—Epoxy resins modified by unsaturated compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
JP2012513928A 2009-06-02 2010-06-01 純粋ｐｅｇ−脂質コンジュゲート Pending JP2012528857A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21762709P 2009-06-02 2009-06-02
US61/217,627 2009-06-02
US28406509P 2009-12-12 2009-12-12
US61/284,065 2009-12-12
PCT/US2010/001590 WO2010141069A2 (en) 2009-06-02 2010-06-01 Pure peg-lipid conjugates

Publications (2)

Publication Number Publication Date
JP2012528857A true JP2012528857A (ja) 2012-11-15
JP2012528857A5 JP2012528857A5 (enExample) 2013-08-15

Family

ID=43298359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012513928A Pending JP2012528857A (ja) 2009-06-02 2010-06-01 純粋ｐｅｇ−脂質コンジュゲート

Country Status (15)

Country Link
US (1) US20110040113A1 (enExample)
EP (1) EP2437756A2 (enExample)
JP (1) JP2012528857A (enExample)
KR (1) KR20120039564A (enExample)
CN (1) CN102665685A (enExample)
AP (1) AP2012006053A0 (enExample)
AU (1) AU2010257181A1 (enExample)
BR (1) BRPI1010175A2 (enExample)
CA (1) CA2763819A1 (enExample)
CL (1) CL2011003049A1 (enExample)
CO (1) CO6511284A2 (enExample)
IL (1) IL216719A0 (enExample)
MX (1) MX2011012823A (enExample)
WO (1) WO2010141069A2 (enExample)
ZA (1) ZA201109366B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013100492A (ja) * 2011-10-17 2013-05-23 Nof Corp ジアシルグリセロールと結合した分岐型ポリエチレングリコール、その製造方法およびポリエチレングリコール修飾リポソーム
JP2016539165A (ja) * 2013-12-05 2016-12-15 ウー, ニエンWU, Nian 薬物転送技術のための高分子−炭水化物共役体
JP2018521152A (ja) * 2015-06-23 2018-08-02 ウー, ニエンWU, Nian 高分子−シクロデキストリン−脂質共役体
WO2019181984A1 (ja) * 2018-03-20 2019-09-26 日油株式会社 分岐型単分散ポリエチレングリコール、中間体およびその製造方法
JP2019172993A (ja) * 2018-03-29 2019-10-10 日油株式会社 トリチル基含有単分散ポリエチレングリコールの精製方法
JP2022041088A (ja) * 2020-08-31 2022-03-11 ジェイ－ネットワーク，インコーポレイテッド 表皮内の保湿関連物質の発現増強剤
JP2025513901A (ja) * 2022-04-22 2025-04-30 ティエンジン アシムケム ファーマシューティカルズ カンパニー リミテッド ポリエチレングリコール－グリセリン誘導体及びその中間体それぞれの製造方法

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
US20120202890A1 (en) 2011-02-08 2012-08-09 Nian Wu Polymer-carbohydrate-lipid conjugates
US20120232169A1 (en) * 2011-03-07 2012-09-13 Biozone Pharmaceuticals, Inc. Highly monodisperse branched peg-lipid conjugates
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
US8883177B2 (en) * 2011-06-28 2014-11-11 Nian Wu Pharmaceutical compositions for parenteral administration
MX363822B (es) * 2012-08-21 2019-04-04 Opko Pharmaceuticals Llc Formulaciones de liposomas.
US11458199B2 (en) 2012-08-21 2022-10-04 Opko Pharmaceuticals, Llc Liposome formulations
US8980839B2 (en) 2012-08-24 2015-03-17 Ocular Technologies Sarl Topical aqueous nanomicellar, ophthalmic solutions and uses thereof
WO2015021044A1 (en) * 2013-08-05 2015-02-12 University Of Rochester Compositions and methods for stimuli-responsive release of a therapeutic agent
JP6629736B2 (ja) * 2013-12-20 2020-01-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ １以上の疎水性ドメインおよびｐｅｇ部分を含む親水性ドメインを含む、細胞を結合するのに有用な化合物
CN105829886B (zh) 2013-12-20 2018-04-03 豪夫迈·罗氏有限公司 使用包含聚乙二醇部分的化合物在支持物上固定细胞的方法
JP6461973B2 (ja) * 2013-12-20 2019-01-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ２以上の疎水性ドメインおよびｐｅｇ部分を含む親水性ドメインを含む化合物の、細胞の安定化のための使用
AU2015360794B2 (en) 2014-12-08 2021-07-08 The Board Of Regents Of The University Of Texas System Lipocationic polymers and uses thereof
JP7041616B2 (ja) 2015-09-14 2022-03-24 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム リポカチオン性デンドリマーおよびその使用
PL3373976T3 (pl) 2015-11-10 2024-06-24 Sun Pharmaceutical Industries Limited Preparaty do stosowania miejscowego i ich zastosowanie
JP7080172B2 (ja) 2015-12-10 2022-06-03 モデルナティエックス インコーポレイテッド 治療薬の送達のための組成物及び方法
CN106905120B (zh) * 2015-12-21 2020-04-28 北京键凯科技股份有限公司 Y型多缩乙二醇衍生物及其制备方法
US10918694B2 (en) 2016-02-29 2021-02-16 Sun Pharma Global Fze Topical cyclosporine-containing formulations and uses thereof
AU2017267634C1 (en) 2016-05-16 2022-05-26 The Board Of Regents Of The University Of Texas System Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
PL3458074T3 (pl) 2016-05-16 2024-11-12 Board Of Regents Of The University Of Texas System KOMPOZYCJA DO DOSTARCZANIA tRNA W POSTACI NANOCZĄSTEK I SPOSOBY ICH STOSOWANIA
WO2019191597A1 (en) * 2018-03-30 2019-10-03 The Board Of Regents Of The University Of Oklahoma Very long chain saturated fatty acid compounds, compositions containing same, and methods of use
US12357580B2 (en) 2018-06-19 2025-07-15 The Board Of Regents Of The University Of Texas System Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
CN112996519B (zh) 2018-09-04 2025-02-28 德克萨斯大学系统董事会 用于核酸的器官特异性递送的组合物和方法
AU2019335055B2 (en) 2018-09-04 2025-05-29 The Board Of Regents Of The University Of Texas System Compositions and methods for organ specific delivery of nucleic acids
US12383508B2 (en) * 2018-09-19 2025-08-12 Modernatx, Inc. High-purity peg lipids and uses thereof
CN116615235A (zh) 2020-10-09 2023-08-18 得克萨斯州大学系统董事会 融合前稳定的hmpv f蛋白
JP6860739B1 (ja) * 2020-11-20 2021-04-21 ジェイ−ネットワーク，インコーポレイテッド 表皮内の抗酸化物質の発現増強剤
CN114685778B (zh) * 2020-12-30 2023-10-17 苏州艾博生物科技有限公司 长循环阳离子脂质体的合成方法
AU2021425941A1 (en) 2021-02-08 2023-08-17 The Board Of Regents Of The University Of Texas System Unsaturated dendrimers compositions,related formulations, and methods of use thereof
IL306007A (en) 2021-03-23 2023-11-01 Recode Therapeutics Inc Polynucleotide preparations, related formulations and methods of using them
US20240207442A1 (en) 2021-04-22 2024-06-27 The Board Of Regents Of The University Of Texas System All-in-one dendrimer-based lipid nanoparticles enable precise hdr-mediated gene editing in vivo
EP4342929A4 (en) 2021-06-30 2024-10-30 Jenkem Technology Co. Ltd. (Tianjin) POLYETHYLENE GLYCOL LIPID AND ITS USE
CN113461929B (zh) * 2021-07-13 2023-04-21 浙江倍合德制药有限公司 一种tpgs系列产品的精制提纯方法
CN116410460B (zh) * 2021-12-29 2025-08-05 辅必成（上海）医药科技有限公司 一种1,2-二肉豆蔻酰-rac-甘油-3-甲氧基聚乙二醇2000的制备方法
CN114507342B (zh) * 2022-03-18 2024-03-19 江苏东南纳米材料有限公司 一种1,2-二肉豆蔻酰-rac-甘油-3-甲氧基聚乙二醇及其中间体的制备方法
US20250235404A1 (en) * 2022-04-05 2025-07-24 Capstan Therapeutics, Inc. Peg-lipids and lipid nanoparticles
CN117003807A (zh) * 2022-04-28 2023-11-07 北京科兴中维生物技术有限公司 一种结构脂质化合物及其制备方法和用途
IL320164A (en) * 2022-11-15 2025-06-01 Evonik Operations Gmbh Polyoxyalkylene-2,1-dimyristoyl-glycerol compounds where the polyoxyalkylene is poly(ethylene oxide) having C1 to C3-alkyloxymethyl side chains
WO2024123633A1 (en) 2022-12-08 2024-06-13 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
CN120569211A (zh) 2023-01-09 2025-08-29 得克萨斯州大学系统董事会 融合前稳定的人副流感病毒3f蛋白
CN116178733B (zh) * 2023-03-03 2023-08-01 浙江博美生物技术有限公司 一种基于三官能团氨基酸的支化单分散peg衍生物、制备方法和应用
US12364773B2 (en) 2023-12-01 2025-07-22 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
WO2025137646A1 (en) 2023-12-22 2025-06-26 Recode Therapeutics, Inc. Gene editing methods and compositions for treating cystic fibrosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827533A (en) * 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US7141552B2 (en) * 2000-01-10 2006-11-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
NZ581166A (en) * 2003-09-15 2011-06-30 Protiva Biotherapeutics Inc Polyethyleneglycol-modified lipid compounds and uses thereof
WO2006007712A1 (en) * 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
WO2006051405A2 (en) * 2004-11-12 2006-05-18 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
EP2219587A4 (en) * 2007-11-14 2012-11-21 Univ California STEROL-MODIFIED AMPHIPHILE LIPIDES

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013100492A (ja) * 2011-10-17 2013-05-23 Nof Corp ジアシルグリセロールと結合した分岐型ポリエチレングリコール、その製造方法およびポリエチレングリコール修飾リポソーム
JP2016539165A (ja) * 2013-12-05 2016-12-15 ウー, ニエンWU, Nian 薬物転送技術のための高分子−炭水化物共役体
JP7196378B2 (ja) 2015-06-23 2022-12-27 ウー，ニエン 高分子－シクロデキストリン－脂質共役体
JP2018521152A (ja) * 2015-06-23 2018-08-02 ウー, ニエンWU, Nian 高分子−シクロデキストリン−脂質共役体
JP7216332B2 (ja) 2018-03-20 2023-02-01 日油株式会社 分岐型単分散ポリエチレングリコール、中間体およびその製造方法
JP2019167532A (ja) * 2018-03-20 2019-10-03 日油株式会社 分岐型単分散ポリエチレングリコール、中間体およびその製造方法
WO2019181984A1 (ja) * 2018-03-20 2019-09-26 日油株式会社 分岐型単分散ポリエチレングリコール、中間体およびその製造方法
US11905367B2 (en) 2018-03-20 2024-02-20 Nof Corporation Branched monodispersed polyethylene glycol, intermediate and methods for producing same
JP2019172993A (ja) * 2018-03-29 2019-10-10 日油株式会社 トリチル基含有単分散ポリエチレングリコールの精製方法
JP7177392B2 (ja) 2018-03-29 2022-11-24 日油株式会社 トリチル基含有単分散ポリエチレングリコールの精製方法
US11680137B2 (en) 2018-03-29 2023-06-20 Nof Corporation Method for purifying trityl group-containing monodispersed polyethylene glycol
JP2022041088A (ja) * 2020-08-31 2022-03-11 ジェイ－ネットワーク，インコーポレイテッド 表皮内の保湿関連物質の発現増強剤
JP2025513901A (ja) * 2022-04-22 2025-04-30 ティエンジン アシムケム ファーマシューティカルズ カンパニー リミテッド ポリエチレングリコール－グリセリン誘導体及びその中間体それぞれの製造方法

Also Published As

Publication number Publication date
WO2010141069A3 (en) 2012-04-12
CO6511284A2 (es) 2012-08-31
BRPI1010175A2 (pt) 2016-03-29
MX2011012823A (es) 2012-06-25
EP2437756A2 (en) 2012-04-11
IL216719A0 (en) 2012-02-29
CL2011003049A1 (es) 2012-07-13
ZA201109366B (en) 2012-08-29
AU2010257181A1 (en) 2012-01-12
CN102665685A (zh) 2012-09-12
CA2763819A1 (en) 2010-12-09
KR20120039564A (ko) 2012-04-25
WO2010141069A2 (en) 2010-12-09
US20110040113A1 (en) 2011-02-17
AP2012006053A0 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
JP2012528857A (ja) 純粋ｐｅｇ−脂質コンジュゲート
WO2012122144A1 (en) Highly monodisperse branched peg-lipid conjugates
EP2393472B1 (en) Amphiphile prodrugs
JP6948313B2 (ja) 治療剤の細胞内送達のための化合物および組成物
KR20230144574A (ko) 폴리옥사졸린-지질 접합체, 및 이를 포함하는 지질 나노입자 및 제약 조성물
EP2310363B1 (en) Anticancer oral formulation
CZ2002928A3 (cs) Taxanová proléčiva
JP2003509386A (ja) タキサン・プロドラッグ
JPH10513187A (ja) 高分子量のポリマーを基剤とするプロドラッグ
KR20100022000A (ko) 소수성 제제를 캡슐화하기 위해 사용되는 혼합 입체화학을 가지는 혼성 블록 공중합체 미셀
AU717922B2 (en) Selectively functionalizable desdendrimers
JP7683120B2 (ja) 核酸トランスフェクション用シクロヘキサンリピドイドおよびその使用方法
WO2024198497A1 (zh) 氨基脂质、脂质纳米颗粒及其应用
CN114213346A (zh) 一种双价可电离脂质化合物、组合物及其应用
WO2025180343A1 (zh) 喹啉类脂质衍生物及其用途
EP4644379A1 (en) Lipid compound and lipid nanoparticle composition
EP2561891A2 (en) Means and methods of enhancing delivery to biological systems
JP3538606B2 (ja) パクリタキセルまたはその誘導体の残基を含む水溶性プロドラッグ化合物、その製造方法及びそれを含む薬剤組成物
CN101485887A (zh) 5-氟尿嘧啶-sn2-磷脂酰胆碱共聚物及其制备方法和用途
WO2011139343A2 (en) Amino acid linked peg-lipid conjugates
TW202206106A (zh) 一類載藥的大分子及其製備方法
US11806407B2 (en) Refillable drug delivery by affinity homing
JP2025540651A (ja) 活性物質送達のための脂質化合物および組成物
WO2006004935A2 (en) Pegylated cardiolipin analogs, methods of synthesis, and uses thereof
AU2023379598A1 (en) Ionizable lipids and lipid nanoparticle compositions for the delivery of nucleic acids

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130603

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20131015